TwinBeech Capital’s BridgeBio Pharma BBIO Stock Holding History

TwinBeech Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-321,811	Closed	-$11.1M	–	649
2025 Q1	$11.1M	Buy	+321,811	New	+$10.9M	0.2%	135
2024 Q4	–	Sell	-77,798	Closed	-$1.98M	–	622
2024 Q3	$1.98M	Sell	77,798 -263,449	-77%	-$6.92M	0.04%	409
2024 Q2	$8.64M	Buy	+341,247	New	+$9.33M	0.17%	153
2023 Q4	–	Sell	-107,409	Closed	-$2.83M	–	654
2023 Q3	$2.83M	Buy	+107,409	New	+$3.05M	0.05%	355
2023 Q1	–	Sell	-264,325	Closed	-$2.01M	–	618
2022 Q4	$2.01M	Buy	+264,325	New	+$2.53M	0.04%	439
2022 Q1	–	Sell	-54,398	Closed	-$907K	–	501
2021 Q4	$907K	Buy	54,398 +45,442	+507%	+$1.92M	0.05%	359
2021 Q3	$420K	Buy	+8,956	New	+$480K	0.03%	453

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TwinBeech Capital's BBIO Position: Q2 2025 in Review

TwinBeech Capital sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 321,811 shares — an estimated $11.1M sold.

TwinBeech Capital first reported a position in BBIO in Q3 2021 and held it in 7 quarters. The position peaked at $11.1M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

TwinBeech Capital reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 321,811 BridgeBio Pharma shares in Q2 2025, an estimated $11.1M.
TwinBeech Capital first reported a position in BridgeBio Pharma in Q3 2021 and held it in 7 quarters.
TwinBeech Capital's BridgeBio Pharma position peaked at $11.1M in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.